Anatara Animal Health Assets Update
Anatara Animal Health Assets Update
Brisbane, Aug 5, 2019 AEST (ABN Newswire) - Anatara Lifesciences (ASX:ANR) provides an update on the strategic evaluation of Detach(R), its non-antibiotic animal health asset which aids in the control of diarrhoeal disease in piglets (known as scour), with potential application in other livestock animals, aquaculture and companion animals.

Market Opportunity for Detach(R) in piglets

Scour (diarrhoea) in piglets is an expensive, debilitating and in some cases, life-threatening condition. Increasing survivability and providing health benefits to pre-weaning piglets has been at the core of the development of Detach(R) since the Company was listed in 2014.

As Anatara moves forward, the Board believes that a substantial market opportunity for Detach(R) exists, with more pressure than ever on producers to reduce their antibiotic use and find suitable alternatives which minimise illnesses, such as scour, on farms. Effective, registered alternatives to antibiotics for scour prevention in piglets are limited. Historically, zinc oxide has been widely used by pig producers as an alternative to antibiotics for scour control and treatment in piglets. However, from 2022, high dosage zinc oxide will no longer be used as a therapeutic agent in the European Union and as such, new alternatives are required.

Detach(R) benefits from concerns over traditional antimicrobials. The global threat of antibiotic resistance continues to gain headlines and the demand for action to reduce the use of antibiotics in livestock production grows.

Following close review, Anatara has determined the best way to launch Detach(R) into the Australian market is via an agreement with an animal health partner. Anatara will continue to explore options to develop then commercialise Detach(R) through animal health partner companies.

Regulatory approval of Detach(R) in overseas markets

Anatara has received approval for its Detach(R) oral drench from the Australian Pesticides and Veterinary Medicines Authority (APVMA) for sale of the product in Australia. This allows for potential fast track product registration within 12 months of date of submission into major pig markets in South East Asia, such as Vietnam, Myanmar and Philippines. However, other individual countries have varying requirements for regulatory approval, with many requiring additional in-country field trials.

In conjunction with an animal health partner, in an effort to meet emerging overseas market trends and expand the market opportunity for Detach(R), Anatara would seek to develop new formulations and administration methods. Anatara has the technical know-how to make these formulation changes and would work closely with a partner to develop and commercialise new presentations of Detach(R) for overseas markets.

Development of Detach(R) for species other than piglets

Anatara has further evaluated the regulatory requirements for species other than piglets in each of the larger markets and believes that considerable development work is required for Detach(R) to be approved for use in other species. However, a market opportunity exists in those markets.

Anatara is exploring options, through animal health companies, to develop then commercialise Detach(R) in multiple species. Anatara has been approached by multi-national animal health companies regarding availability of Detach(R) for licensing.

Options to deliver on the global value of Anatara's animal health assets

CEO Steve Lydeamore commented, "We are grateful for the support of shareholders while we work through this review process. We continue to believe in the value of Anatara's animal health assets, however it is clear that further investment is required to realise this. It is our intent to achieve success through partnering with multi-national animal health companies."

Anatara continues to evaluate potential licensing partners including those with which we have had prior discussions and additional companies. Anatara has engaged an animal health business development consultant to assist in this process. We will continue to provide updates to the market as these activities progress.


About Anatara Lifesciences Ltd

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.

    


Contact

Investor and Media inquiries

Steven Lydeamore
Chief Executive Officer
Anatara Lifesciences Ltd
T: +61-438-027-172
E: slydeamore@anatara.com

Sue MacLeman
Chair
Anatara Lifesciences Ltd
T: +61-437-211-200
E: smacleman@anatara.com



Related Companies

Anatara Lifesciences Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 69) (Last 30 Days: 349) (Since Published: 1616)